The combination of mitomycin (8 mg/m(2), i.v., day 1), vindesine (3 mg /m(2), i.v., days 1 and 8), and cisplatin (60 mg/m(2), i.v., day 1) (MiViP) was evaluated in 12 patients with recurrent carcinoma of the cervix. The number of treatment courses ranged from two to eight, with a median of five. Three patients achieved complete remission and six patients showed partial remission, giving and overall response rate of 75%. The median survival was 18 months, with 22 months for responding patients, and 5 months for nonresponding patients (p < 0.01). The major toxicity was myelosuppression. We conclude that MiViP can effectively be used in recurrent carcinoma of the cervix.